No Data
No Data
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $20
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
No Data
No Data
QMengColdJoke : I am buying back, this designation itself means nothing but in the end will make final approval easier and faster.